Stock Events

Stock Events

Aerovate Therapeutics 

$2.68
45
+$0+0% Monday 20:00

Statistics

Day High
2.77
Day Low
2.63
52W High
884.98
52W Low
2.63
Volume
981,795
Avg. Volume
7,570
Mkt Cap
0
P/E Ratio
-
Dividend Yield
6,268.66%
Dividend
168

Upcoming

27
APR
Dividend Ex
Estimated
 
28
APR
Dividend Payment
Estimated
 
29
APR
Dividend Ex
Estimated
 
29
APR
Dividend Payment
Estimated
 
26
APR 27
Dividend Ex
Estimated
 
28
APR 27
Dividend Payment
Estimated
 

Dividends

6,268.66%Dividend Yield
Apr 26
$84
Apr 26
$84
Apr 25
$84
Apr 25
$84
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11AugExpected
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
-12.1
-8.22
-4.34
-0.47
Expected EPS
-3.15
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-69.63MNet Income

Analyst Ratings

$29.20Average Price Target
The highest estimate is 39.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVTE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it develops and markets therapies for treating cystic fibrosis, a space where Aerovate Therapeutics is also aiming to innovate with its cardiovascular and pulmonary disease treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the research and development of drugs for pulmonary diseases among other areas, making it a direct competitor to Aerovate Therapeutics in the pulmonary treatment market.
Arvinas
ARVN
Mkt Cap744.45M
Arvinas, Inc. is focused on developing therapies for cancers and other difficult-to-treat diseases, including lung diseases, which puts it in competition with Aerovate Therapeutics.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation works on the discovery, development, and commercialization of proprietary therapeutics, including for serious pulmonary conditions, competing with Aerovate Therapeutics.
Galapagos NV
GLPG
Mkt Cap2.09B
Galapagos NV is engaged in the discovery and development of small molecule medicines with novel modes of action, several of which target pulmonary diseases, making it a competitor.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. focuses on enzyme replacement therapies and other drug developments for rare genetic diseases, some of which involve pulmonary aspects, competing with Aerovate.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, Inc. is known for its focus on RNA-targeted therapeutics, including treatments for rare diseases, some of which may overlap with Aerovate Therapeutics' focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. works on RNAi therapeutics for the treatment of rare diseases, including those affecting the lungs, making it a competitor to Aerovate Therapeutics.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes medicines for the treatment of serious medical conditions, including pulmonary diseases, competing with Aerovate Therapeutics.

About

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Timothy P. Noyes M.B.A.
Employees
4
Country
US
ISIN
US0080641071

Listings

XNAS
US
JBIO
BOATS
BOATS
JBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Aerovate Therapeutics stock price today?▼
The current price of AVTE is $2.68 USD — it has increased by +0% in the past 24 hours. Watch Aerovate Therapeutics stock price performance more closely on the chart.
What is Aerovate Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aerovate Therapeutics stocks are traded under the ticker AVTE.
Is Aerovate Therapeutics stock price growing?▼
AVTE stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Aerovate Therapeutics has showed a +6.77% increase.
What is Aerovate Therapeutics revenue for the last year?▼
Aerovate Therapeutics revenue for the last year amounts to 0 USD.
What is Aerovate Therapeutics net income for the last year?▼
AVTE net income for the last year is -69.63M USD.
Does Aerovate Therapeutics pay dividends?▼
Yes, AVTE dividends are paid en. The last dividend per share was 84 USD. As of today, Dividend Yield (FWD)% is 6,268.66%.
How many employees does Aerovate Therapeutics have?▼
As of April 03, 2026, the company has 4 employees.
In which sector is Aerovate Therapeutics located?▼
Aerovate Therapeutics operates in the Health Care sector.
When did Aerovate Therapeutics complete a stock split?▼
The last stock split for Aerovate Therapeutics was on April 29, 2025 with a ratio of 1:35.
Where is Aerovate Therapeutics headquartered?▼
Aerovate Therapeutics is headquartered in Waltham, US.